As expected, CLEC9A was differentially correlated with multiple cytotoxic markers (e.g., CD8A, CD8B, FCGR3A, GZMB, GZMH, KLRK1, TBX21), as well as IFN-II pathway genes (e.g., CXCL9, CXCL10, CXCR3, GBP1, GBP2, IFI30, IFNG, IL12B, PSMB8), two MHC-I-encoding HLA genes (HLA-B and HLA-F), and eight MHC-II-encoding HLA genes in IBM samples. The gene discussed is IFI30; the disease is inclusion body myositis.